The Role of Cost-Effectiveness Analysis in Managed-Care Decisions
- 23 Downloads
This article considers the role of cost-effectiveness studies in the formulary and disease-state management decisions of managed-care entities. In a recently published symposium volume [Soc Sci Med 1997; 45 (4): 505-647], US managed- care entities were found to be among the leaders in applying cost-effectiveness studies to healthcare decisions. At the same time, a number of barriers were identified that hinder their wider usage in the managed-care sector. These factors are analysed in this paper along with the prospects for future changes. The potential roles for government policy in this area are also discussed in the final section of the article.
KeywordsAdis International Limited Misoprostol Federal Trade Commission Pharmacy Benefit Management Total Drug Expenditure
Unable to display preview. Download preview PDF.
- 5.Rittenhouse BE O’Brien BJ. Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996: 1215–23Google Scholar
- 9.Angstrom G.Mayo Clinic full speed ahead for guidelines. 1996 Drug outcomes sourcebook. New York: Faulkner and Gray, 1996; 72–4Google Scholar
- 12.Neumann P. Government uses of cost-effectiveness information on drugs. In: Calfee J, editor. Policy issues in pharmaceutical cost-effectiveness research. Washington, DC: AEI Press, 1998Google Scholar
- 14.Food and Drug Administration. Principles for the review of pharmacoeconomic promotion. Draft manuscript. Rockville, Maryland, USA: FDA, Mar 1995Google Scholar
- 15.Grabowski JG. Pharmaceutical innovation, cost effectiveness, research and emerging regulatory issues. In: Calfee J, editor. Policy issues in pharmaceutical cost-effectiveness research. Washington DC: AEI Press, 1998Google Scholar
- 17.Drummond M. Government use of cost-effectiveness research in decisions about the reimbursement and use of pharmaceuticals lessons from overseas. In: Calfee J, editor. Policy issues in pharmaceutical cost-effectiveness research. Washington DC: AEI Press, 1998Google Scholar
- 18.Federal Trade Commission, Business of Economic and Consumer Protection. In the matter of pharmaceutical marketing and information exchange in the managed care environments, public hearings. Docket no. 95N-0228. Washington: FTC, Jan 16, 1995Google Scholar
- 19.Inside Washington’s FDA Week. ‘FTC worried about how FDA will review health care economic claims.’ 1998 Feb 20;4(8): 1–2Google Scholar
- 20.Inside Washington’s FDA Week. FDA seeks help with health care economic promotion guide. 1998 Feb 27; 4(9): 13Google Scholar